CollPlant to Present at the 2025 International Conference on Biofabrication
CLGN(NASDAQ:CLGN) REHOVOT, Israel, Sept. 2, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced its participation...
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
CLGNREHOVOT, Israel, Aug. 25, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced that senior...
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CLGN- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire - - Raised $3.6 million in registered direct offering in second quarter - REHOVOT, Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative...
CollPlant Biotechnologies Expands Agreement With STEMCELL Technologies, Broadening Use Of CollPlant's rhCollagen In Clinical And Commercial Applications
CLGNCollPlant Secures European Patent For rhCollagen-Based Soft Tissue Fillers And Regenerative Implants
CLGND. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target
CLGNCollPlant Raises $3.6M in Stock and Warrant Deal to Fund Regenerative Medicine Growth
CLGND. Boral Capital Maintains Buy on CollPlant Biotechnologies, Lowers Price Target to $12
CLGNCollPlant Biotechnologies Q1 2025 Adj. EPS $(0.10) Misses $(0.04) Estimate, Sales $2.06M Miss $2.65M Estimate
CLGNEarnings Preview: CollPlant Biotechnologies
CLGND. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target
CLGNCollPlant Biotechnologies FY 2024 Adj. EPS $(1.30) Beats $(1.44) Estimate, Sales $515.000K Miss $1.640M Estimate
CLGNCollPlant Expands Vergenix STR Distribution to Europe and Asia, Targets Tendon Injury Treatments
CLGND. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target
CLGNCollPlant Updates On AbbVie Dermal Filler Program And Achievement Of Contingent Payment
CLGNCollPlant Biotechnologies Initiates Cost Cutting Plan, To Cut Workforce By Approximately 20%
CLGNCollPlant Biotechnologies Says Granted U.S. Patent No. 12,186,449 Related To Its Photocurable Dermal Filler Product Candidate
CLGN